Betrixaban
As of the edition of 20 October 2026, Betrixaban is a small molecule: marketed, first approved in 2017 (US); acts on F10; US protection ends in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Bevyxxa
- First approved
- 23 June 2017 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Portola Pharmaceuticals
- Registered trials
- 11, 2 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2026.
The last listed US drug-substance patent ends in 2026. The application that gives this date is held by Portola Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Betrixaban.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| F10 | Coagulation factor X | P00742 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 4 | 3 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Portola Pharmaceuticals | Originator and Lead sponsor of trials | 2006 to now |